vs
ICU MEDICAL INC（ICUI）与UiPath, Inc.（PATH）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是UiPath, Inc.的1.3倍（$540.7M vs $411.1M），UiPath, Inc.净利率更高（48.4% vs -2.9%，领先51.3%），UiPath, Inc.同比增速更快（15.9% vs -14.1%），ICU MEDICAL INC自由现金流更多（$36.0M vs $25.1M），过去两年UiPath, Inc.的营收复合增速更高（0.7% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
UiPath是一家全球化软件企业，专注于开发人工智能、智能自动化及流程编排类软件，其产品支持用户搭建与调度AI代理，实现复杂业务流程、工作流的自动化运行，助力各行业客户提升运营效率、降低人力成本。
ICUI vs PATH — 直观对比
营收规模更大
ICUI
是对方的1.3倍
$411.1M
营收增速更快
PATH
高出30.1%
-14.1%
净利率更高
PATH
高出51.3%
-2.9%
自由现金流更多
ICUI
多$10.8M
$25.1M
两年增速更快
PATH
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $411.1M |
| 净利润 | $-15.7M | $198.8M |
| 毛利率 | 37.5% | 83.3% |
| 营业利润率 | 1.0% | 3.2% |
| 净利率 | -2.9% | 48.4% |
| 营收同比 | -14.1% | 15.9% |
| 净利润同比 | 34.0% | 1966.2% |
| 每股收益（稀释后） | $-0.63 | $0.37 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIPATH
| Q4 25 | $540.7M | $411.1M | ||
| Q3 25 | $537.0M | $361.7M | ||
| Q2 25 | $548.9M | $356.6M | ||
| Q1 25 | $604.7M | $423.6M | ||
| Q4 24 | $629.8M | $354.7M | ||
| Q3 24 | $589.1M | $316.3M | ||
| Q2 24 | $596.5M | $335.1M | ||
| Q1 24 | $566.7M | $405.3M |
净利润ICUIPATH
| Q4 25 | $-15.7M | $198.8M | ||
| Q3 25 | $-3.4M | $1.6M | ||
| Q2 25 | $35.3M | $-22.6M | ||
| Q1 25 | $-15.5M | $51.8M | ||
| Q4 24 | $-23.8M | $-10.7M | ||
| Q3 24 | $-33.0M | $-86.1M | ||
| Q2 24 | $-21.4M | $-28.7M | ||
| Q1 24 | $-39.5M | $33.9M |
毛利率ICUIPATH
| Q4 25 | 37.5% | 83.3% | ||
| Q3 25 | 37.4% | 82.2% | ||
| Q2 25 | 37.9% | 82.1% | ||
| Q1 25 | 34.7% | 84.8% | ||
| Q4 24 | 36.1% | 82.0% | ||
| Q3 24 | 34.8% | 80.0% | ||
| Q2 24 | 34.8% | 83.5% | ||
| Q1 24 | 32.7% | 86.8% |
营业利润率ICUIPATH
| Q4 25 | 1.0% | 3.2% | ||
| Q3 25 | 2.6% | -5.6% | ||
| Q2 25 | 1.9% | -4.6% | ||
| Q1 25 | 2.1% | 7.9% | ||
| Q4 24 | 6.0% | -12.2% | ||
| Q3 24 | 1.4% | -32.7% | ||
| Q2 24 | 1.3% | -14.8% | ||
| Q1 24 | -1.9% | 3.7% |
净利率ICUIPATH
| Q4 25 | -2.9% | 48.4% | ||
| Q3 25 | -0.6% | 0.4% | ||
| Q2 25 | 6.4% | -6.3% | ||
| Q1 25 | -2.6% | 12.2% | ||
| Q4 24 | -3.8% | -3.0% | ||
| Q3 24 | -5.6% | -27.2% | ||
| Q2 24 | -3.6% | -8.6% | ||
| Q1 24 | -7.0% | 8.4% |
每股收益（稀释后）ICUIPATH
| Q4 25 | $-0.63 | $0.37 | ||
| Q3 25 | $-0.14 | $0.00 | ||
| Q2 25 | $1.43 | $-0.04 | ||
| Q1 25 | $-0.63 | $0.09 | ||
| Q4 24 | $-0.97 | $-0.02 | ||
| Q3 24 | $-1.35 | $-0.15 | ||
| Q2 24 | $-0.88 | $-0.05 | ||
| Q1 24 | $-1.63 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.4B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $1.9B |
| 总资产 | $4.1B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICUIPATH
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.6B | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | $308.6M | $1.6B | ||
| Q3 24 | $312.5M | $1.7B | ||
| Q2 24 | $302.6M | $1.9B | ||
| Q1 24 | $251.4M | $1.9B |
股东权益ICUIPATH
| Q4 25 | $2.1B | $1.9B | ||
| Q3 25 | $2.1B | $1.7B | ||
| Q2 25 | $2.1B | $1.7B | ||
| Q1 25 | $2.0B | $1.8B | ||
| Q4 24 | $2.0B | $1.7B | ||
| Q3 24 | $2.0B | $1.8B | ||
| Q2 24 | $2.0B | $2.0B | ||
| Q1 24 | $2.1B | $2.0B |
总资产ICUIPATH
| Q4 25 | $4.1B | $2.9B | ||
| Q3 25 | $4.1B | $2.6B | ||
| Q2 25 | $4.1B | $2.6B | ||
| Q1 25 | $4.2B | $2.9B | ||
| Q4 24 | $4.2B | $2.7B | ||
| Q3 24 | $4.3B | $2.7B | ||
| Q2 24 | $4.3B | $2.8B | ||
| Q1 24 | $4.3B | $3.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $28.3M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $25.1M |
| 自由现金流率自由现金流/营收 | 6.6% | 6.1% |
| 资本支出强度资本支出/营收 | 4.6% | 0.8% |
| 现金转化率经营现金流/净利润 | — | 0.14× |
| 过去12个月自由现金流最近4个季度 | $91.8M | — |
8季度趋势，按日历期对齐
经营现金流ICUIPATH
| Q4 25 | $60.6M | $28.3M | ||
| Q3 25 | $56.7M | $41.6M | ||
| Q2 25 | $11.2M | $119.0M | ||
| Q1 25 | $51.3M | $146.1M | ||
| Q4 24 | $40.2M | $28.1M | ||
| Q3 24 | $36.1M | $46.4M | ||
| Q2 24 | $82.0M | $100.0M | ||
| Q1 24 | $45.8M | $145.6M |
自由现金流ICUIPATH
| Q4 25 | $36.0M | $25.1M | ||
| Q3 25 | $27.6M | — | ||
| Q2 25 | $-8.5M | $106.2M | ||
| Q1 25 | $36.7M | $138.7M | ||
| Q4 24 | $16.1M | $23.2M | ||
| Q3 24 | $16.2M | $45.0M | ||
| Q2 24 | $62.5M | $98.8M | ||
| Q1 24 | $29.9M | $141.8M |
自由现金流率ICUIPATH
| Q4 25 | 6.6% | 6.1% | ||
| Q3 25 | 5.1% | — | ||
| Q2 25 | -1.5% | 29.8% | ||
| Q1 25 | 6.1% | 32.7% | ||
| Q4 24 | 2.6% | 6.5% | ||
| Q3 24 | 2.7% | 14.2% | ||
| Q2 24 | 10.5% | 29.5% | ||
| Q1 24 | 5.3% | 35.0% |
资本支出强度ICUIPATH
| Q4 25 | 4.6% | 0.8% | ||
| Q3 25 | 5.4% | 0.0% | ||
| Q2 25 | 3.6% | 3.6% | ||
| Q1 25 | 2.4% | 1.7% | ||
| Q4 24 | 3.8% | 1.4% | ||
| Q3 24 | 3.4% | 0.4% | ||
| Q2 24 | 3.3% | 0.4% | ||
| Q1 24 | 2.8% | 0.9% |
现金转化率ICUIPATH
| Q4 25 | — | 0.14× | ||
| Q3 25 | — | 26.25× | ||
| Q2 25 | 0.32× | — | ||
| Q1 25 | — | 2.82× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 4.29× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
PATH
| Subscription Services | $247.6M | 60% |
| License | $150.0M | 36% |
| Professional Services And Other | $13.5M | 3% |
